Insider · CIK 0001707000
Timothy Eugene Sullivan
cfoofficer
Files at APLS (Apellis Pharmaceuticals, Inc.). First filing Jan 14, 2025, latest Jan 23, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 9
$0 bought, $2.1M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 49Moderate | Apellis Pharmaceuticals, Inc. | $224k 10,287 shares | -10% | - | |
| 44Moderate | Apellis Pharmaceuticals, Inc. | $57k 2,892 shares | -3% | - | |
| 46Moderate | Apellis Pharmaceuticals, Inc. | $86k 3,856 shares | -3% | - | |
| 16Weak | Apellis Pharmaceuticals, Inc. | $280k 10,000 shares | -8% | - | |
| 37Weak | Apellis Pharmaceuticals, Inc. | $1.2M 42,729 shares | -30% | - | |
| 37Weak | Apellis Pharmaceuticals, Inc. | $16k 546 shares | -0% | - | |
| 47Moderate | Apellis Pharmaceuticals, Inc. | $94k 3,088 shares | -2% | - | |
| 44Moderate | Apellis Pharmaceuticals, Inc. | $52k 1,730 shares | -2% | - | |
| 44Moderate | Apellis Pharmaceuticals, Inc. | $62k 2,170 shares | -2% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 28, 2026 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +58,140 | $0.00 | $0 | 152,041 | Jan 30, 2026 |
| Jan 22, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -10,287 | $21.77 | $224k | 93,901 | Jan 23, 2026 |
| Jan 20, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,892 | $19.79 | $57k | 104,188 | Jan 21, 2026 |
| Jan 13, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -3,856 | $22.19 | $86k | 107,080 | Jan 15, 2026 |
| Oct 21, 2025 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +10,000 | $10.03 | $100k | 120,936 | Oct 23, 2025 |
| Oct 21, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -10,000 | $28.03 | $280k | 110,936 | Oct 23, 2025 |
| Oct 21, 2025 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 232,903 | Oct 23, 2025 |
| Sep 8, 2025 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +15,000 | $10.03 | $150k | 143,665 | Sep 10, 2025 |
| Sep 8, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -32,729 | $27.86 | $912k | 110,936 | Sep 10, 2025 |
| Sep 8, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stockindirect: The Timothy E Sullivan Irrevocable Trust of 202310b5-1 | -10,000 | $27.83 | $278k | 60,396 | Sep 10, 2025 |
| Sep 8, 2025 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 242,903 | Sep 10, 2025 |
| Jun 9, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +82,500 | $19.39 | $1.6M | 82,500 | Jun 11, 2025 |
| Jan 29, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -546 | $29.52 | $16k | 128,665 | Jan 30, 2025 |
| Jan 22, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -3,088 | $30.43 | $94k | 129,211 | Jan 23, 2025 |
| Jan 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,730 | $29.96 | $52k | 86,370 | Jan 21, 2025 |
| Jan 21, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +45,929 | $0.00 | $0 | 132,299 | Jan 21, 2025 |
| Jan 13, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,170 | $28.70 | $62k | 88,100 | Jan 14, 2025 |
| Dec 31, 2024 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Common Stock | +1,042 | $14.95 | $16k | 80,216 | Jan 3, 2025 |
| Dec 31, 2024 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Common Stock | +10,054 | $13.85 | $139k | 90,270 | Jan 3, 2025 |
| Dec 31, 2024 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -1,042 | $0.00 | $0 | 23,958 | Jan 3, 2025 |
| Dec 31, 2024 | APLS Apellis Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -10,054 | $0.00 | $0 | 84,946 | Jan 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.